CXCR5 Modified EGFR Chimeric Antigen Receptor Autologous T Cell Therapy

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCXCR5 Modified EGFR Chimeric Antigen Receptor Autologous T Cell Therapy

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionC-X-C motif chemokine receptor 5 antagonists

TargetsC-X-C motif chemokine receptor 5

Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesSecond Affiliated Hospital Of Guangzhou Medical University

China Registration ClassN/A

Develop Information

Active CompaniesSecond Affiliated Hospital Of Guangzhou Medical University

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell Lung

Inactive IndicationsN/A

Other Information

ATC CodeN/A